mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Biden was a longtime member of the Senate Committee on the Judiciary. He chaired it from 1987 to 1995 and was a ranking minority member from 1981 to 1987 and again from 1995 to 1997. As chair, Biden presided over two highly contentious U.S. Supreme Court confirmation hearings. When Robert Bork was nominated in 1988, Biden reversed his approval—given in an interview the previous year—of a hypothetical Bork nomination. Conservatives were angered, but at the hearings' close Biden was praised for his fairness, humor, and courage. Rejecting the arguments of some Bork opponents, Biden framed his objections to Bork in terms of the conflict between Bork's strong originalism and the view that the U.S. Constitution provides rights to liberty and privacy beyond those explicitly enumerated in its text. Bork's nomination was rejected in the committee by a 5–9 vote and then in the full Senate, 42–58. During Clarence Thomas's nomination hearings in 1991, Biden's questions on constitutional issues were often convoluted to the point that Thomas sometimes lost track of them, and Thomas later wrote that Biden's questions were akin to "beanballs". After the committee hearing closed, the public learned that Anita Hill had accused Thomas of making unwelcome sexual comments when they had worked together. Biden had known of some of these charges, but initially shared them only with the committee because Hill was then unwilling to testify.
Due largely to the US EPA's Acid Rain Program, the U.S. has had a 33% decrease in emissions between 1983 and 2002 (see table). This improvement resulted in part from flue-gas desulfurization, a technology that enables SO2 to be chemically bound in power plants burning sulfur-containing coal or petroleum.
Hans Wolfgang Schumann argues that a comparison of the twelve nidanas with the five skhandhas shows that the 12 link chain contains logical inconsistencies, which can be explained when the chain is considered to be a later elaboration. Schumann thus concluded that the twelvefold chain was a later synthesis composed by Buddhist monks, consisting of three shorter lists. These lists may have encompassed nidana 1–4, 5–8, and 8-12. Schumann also proposes that the 12 nidanas are extended over three existences, and illustrates the succession of rebirths. While Buddhaghosa and Vasubandhu maintain a 2-8-2 schema, Schumann maintains a 3-6-3 scheme. According to Richard Gombrich, the twelve-fold list is a combination of two previous lists, the second list beginning with tanha, "thirst", the cause of suffering as described in the second noble truth". The first list consists of the first four nidanas, which reference Vedic cosmogony, as described by Jurewicz. According to Gombrich, the two lists were combined, resulting in contradictions in its reverse version.
Sources: en.wikipedia.org
=== Electronic effects === Owing to inductive effects, the basicity of an amine might be expected to increase with the number of alkyl groups on the amine. Correlations are complicated owing to the effects of solvation which are opposite the trends for inductive effects. Solvation effects also dominate the basicity of aromatic amines (anilines). For anilines, the lone pair of electrons on nitrogen delocalizes into the ring, resulting in decreased basicity. Substituents on the aromatic ring, and their positions relative to the amino group, also affect basicity as seen in the table.
== Early life and education == Pawliszyn was born on May 16, 1954, in Gdańsk, Poland. Pawliszyn began his education in Poland by attending the Gdańsk University of Technology for his Bachelor of Science degree in engineering and Master's degree in bioorganic chemistry. Following this, he moved to the United States for his PhD in analytical chemistry at Southern Illinois University.
, especially noticeable as temperatures exceed 30 °C. The temperature dependence of the electrical conductivity of fully deionized water without CO2 saturation is comparably low in relation to these data.
A clinical study that includes some, but not all, of the eligible patients identified by the researchers during the study registration period. This type of study does not usually have a control group. (NCI) Non-inferiority trial
Sources: en.wikipedia.org
bridge A chemical bond between valence electrons, or an atom or unbranched chain of atoms connecting two different parts of the same molecule; i.e. an intramolecular bond linking different moieties or functional groups.
=== British Empire Medal (BEM) === Alwyn Enoe. For services to Entrepreneurships. The Reverend Dave King, Presiding Bishop, River Sallee Pentecostal Church/Temple of Deliverance, Grenada District. For services to Religious Affairs and Social Work
==== Reduced probability of contamination ==== DMF-based workflows, particularly those using a closed configuration with a top-plate ground electrode, have been shown to be less susceptible to outside contamination compared to some conventional laboratory workflows. This can be attributed to minimal user interaction during automated steps, and the fact that the smaller volumes are less exposed to environmental contaminants than larger volumes which would need to be exposed to open air during mixing. Ruan et al. observed minimal contamination from exogenous nonhuman DNA and no cross-contamination between samples while using their DMF-based digital whole genome sequencing system.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.